ketanserinol: major ketanserin metabolite; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 156394 |
| SCHEMBL ID | 431162 |
| MeSH ID | M0118746 |
| Synonym |
|---|
| ketanserinol |
| 3-[2-[4-[(4-fluorophenyl)-hydroxymethyl]piperidin-1-yl]ethyl]-1h-quinazoline-2,4-dione |
| 76330-73-9 |
| 3-(2-(4-((4-fluorophenyl)hydroxymethyl)-1-piperidinyl)ethyl)-2,4-(1h,3h)quinazolinedione |
| r 46742 |
| r-46742 |
| r 46,742 |
| 2,4(1h,3h)-quinazolinedione, 3-(2-(4-((4-fluorophenyl)hydroxymethyl)-1-piperidinyl)ethyl)- |
| reduced ketanserin |
| SCHEMBL431162 |
| CSAITASUWRGAOT-UHFFFAOYSA-N |
| 3-[2-[4-[(4-fluorophenyl)hydroxymethyl]-1-piperidinyl]ethyl]-2,4(1h,3h)-quinazolinedione |
| 3-(2-{4-[(4-fluorophenyl)(hydroxy)methyl]piperidin-1-yl}ethyl)-2-hydroxyquinazolin-4(3h)-one |
| DTXSID70997695 |
| AKOS040746948 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Pharmacokinetic parameters were calculated using noncompartmental analysis based on a statistical moment theory." | ( Pharmacokinetics of ketanserin in patients with cirrhosis. Benhamou, JP; Berthelot, P; Fraitag, B; Gaudin, C; Hadengue, A; Lebrec, D; Levron, JC, 1990) | 0.28 |
| " Ketanserin had a terminal half-life of 29." | ( Pharmacokinetics of ketanserin in patients with essential hypertension. Hedner, T; Persson, B; Pettersson, A, 1987) | 0.27 |
| " Comparison of plasma Cmax and AUCs indicated that the equilibrium was shifted towards ketanserin-ol." | ( Pharmacokinetic approach to equilibrium between ketanserin and ketanserin-ol. Embrechts, L; Heykants, J; Van Peer, A; Woestenborghs, R, 1986) | 0.27 |
| " ketanserin were characterized by a terminal half-life of 14." | ( Pharmacokinetics of ketanserin and its metabolite ketanserin-ol in man after intravenous, intramuscular and oral administration. Gould, S; Heykants, J; Mills, J; Van Peer, A; Woestenborghs, R, 1986) | 0.27 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The oral bioavailability of 6-hydroxyketanserin was very low, accounting for its low in vivo activity after oral administration." | ( Pharmacokinetic evaluation of the in vitro and in vivo pharmacological profile of the major metabolites of ketanserin in the rat. Awouters, F; Heykants, J; Leysen, JE; Michiels, M; Schuurkes, J; Van Nueten, JM; Woestenborghs, R, 1988) | 0.27 |
| " Its absolute bioavailability was 48%." | ( Pharmacokinetics of ketanserin in patients with essential hypertension. Hedner, T; Persson, B; Pettersson, A, 1987) | 0.27 |
| " administration, peak levels of nearly 200 ng/ml were attained within 10 minutes and the absolute bioavailability was 112 +/- 23%." | ( Pharmacokinetics of ketanserin and its metabolite ketanserin-ol in man after intravenous, intramuscular and oral administration. Gould, S; Heykants, J; Mills, J; Van Peer, A; Woestenborghs, R, 1986) | 0.27 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " These results suggest either a reduction in the oral dosage of ketanserin or an increase in the interval between doses in patients with cirrhosis." | ( Pharmacokinetics of ketanserin in patients with cirrhosis. Benhamou, JP; Berthelot, P; Fraitag, B; Gaudin, C; Hadengue, A; Lebrec, D; Levron, JC, 1990) | 0.28 |
| "The metabolic reduction-oxidation equilibrium between ketanserin and ketanserin-ol was studied after oral dosing of both substances to two healthy volunteers." | ( Pharmacokinetic approach to equilibrium between ketanserin and ketanserin-ol. Embrechts, L; Heykants, J; Van Peer, A; Woestenborghs, R, 1986) | 0.27 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 11 (64.71) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.16) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (17.65%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (82.35%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||